DUSA Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

DUSA 0.0000
price chart
DUSA Pharmaceuticals Is A Small Gem
DUSA Pharmaceuticals, Inc. (DUSA), a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada, and Korea.
Shedding A Little Light On Under-Followed DUSA Pharmaceuticals
Originally DUSA had an agreement with Schering to sell the therapy, but initial sales were poor because of reimbursement issues and DUSA ultimately had to take it over for themselves. With the capital limitations of a small, money-losing company, DUSA ...
Related articles »  
DUSA Pharmaceuticals Shares Tumble After Earnings: Low Growth Ahead?
DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) - based in Wilmington, MA is a dermatology company engaged in the development and commercialization of Levulan photodynamic therapy (PDT).
Related articles »  
Caraco Pharmaceutical Laboratories and DUSA Pharmaceuticals Announce ...
DETROIT and WILMINGTON, Mass., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Caraco Pharmaceutical Laboratories, Ltd. ("CPL"), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), and DUSA Pharmaceuticals, Inc.
Related articles »  
DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent
WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.� (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan� Photodynamic Therapy (PDT), today announced that the United States Patent ...
Related articles »  
DUSA: A Pharmaceutical With Profits Now and Strong Growth Ahead
Newly profitable small-cap biotechnology company DUSA Pharmaceuticals (NASDAQ:DUSA) is an investment with fantastic return opportunities.
Related articles »  
Sun Pharma to buy Dusa for $230 million
Mumbai: Sun Pharmaceuticals Industries Ltd, India's most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million (Rs.1,251 crore). Under the terms of the agreement, a subsidiary of Sun ...
Sun Pharma to acquire US-based DUSA for $230 million  Rediff
Related articles »  
Caliber Imaging & Diagnostics Names Richard C. Christopher to Chief Financial ...
Mr. Christopher served for eight years as Chief Financial Officer of DUSA Pharmaceuticals, Inc., until its sale to Sun Pharmaceuticals Industries Limited in 2012.
Related articles »  
Caliber Imaging & Diagnostics Names New CFO
"During my tenure at DUSA Pharmaceuticals, I came to appreciate the specific challenges facing a small publicly traded company developing new technology for the skin cancer market,� Christopher said. �In my new role at Caliber I.D., I intend to work ...
Do Hedge Funds and Insiders Love SciClone Pharmaceuticals, Inc. (SCLN)?
These stocks are Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Depomed Inc (NASDAQ:DEPO), DUSA Pharmaceuticals Inc (NASDAQ:DUSA), Lannett Company, Inc. (NYSEAMEX:LCI), and Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Related articles »